Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2005-10-27 | Professor Kelly was Senior Research Fellow in Experimental Surgery in the Faculty of Medicine at the University of Sydney and was appointed an Adjunct Professor of the University in May 2004. He developed the (1&3)(1&6)-ß-glucan and isoflavone intellectual property now owned by the Novogen Group. |
| 2006-10-30 | Professor Kelly holds BSc(Vet), BVSc, PhD degrees and has spent nearly 30 years in medical research involving drug development, immunology, surgery and cancer. |
Data sourced from SEC filings. Last updated: 2026-02-03